الفهرس 
Normal Lung PhysiologyOnly 14 pages are availabe for public view
 |  | from | 87 |  |  |
| | | from | 87 | | |
Abstract
to assess the efficacy of prostaglandin E1 (PGE1) in prevention of neonatal respiratory morbidity (NRM) especially transient tachypnea of newborn (TTN) before elective caesarian section (ECS).
Materials and methods: a randomized clinical trial (NCT04780412) was carried out in Ain Shams University maternity hospital between February and August 2020. After exclusion of those who did not meet the inclusion criteria and those who refused to participate, a total of 210 pregnant women between 37 and 38+6 weeks of gestation were allocated to 2 equal groups, a Misoprostol group who received 50 micrograms of vaginal Misoprostol, and a placebo group who received placebo, 90 to 120 minutes before the ECS.
Outcomes: The incidence of TTN, and the need for Neonatal Intensive Care Unit (NICU) admission for respiratory support.
Results: Regarding the incidence of TTN & the need for NICU admission, a significant statistical difference was found between the Misoprostol group (1%), and the Placebo group (17.1%) with a P-value < 0.001. Also, the APGAR scores at 1 and 5 minutes were significantly different among the 2 groups (7.8 ± 0.8, 9.4 ± 0.7 and 7.2 ± 1.3, 8.7 ± 1.5 for the Misoprostol and placebo groups, respectively) with a P-value < 0.001 for both 1 minute and 5 minutes scores.
Conclusion: administration of 50 micrograms of vaginal Misoprostol 90 to 120 minutes before the ECS can significantly reduce the incidence of TTN and the subsequent need for NICU admission.